These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 22532777)

  • 1. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
    Brown-Glaberman U; Stopeck AT
    Biologics; 2012; 6():89-99. PubMed ID: 22532777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.
    Wang X; Yang KH; Wanyan P; Tian JH
    Oncol Lett; 2014 Jun; 7(6):1997-2002. PubMed ID: 24932278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
    Cadieux B; Coleman R; Jafarinasabian P; Lipton A; Orlowski RZ; Saad F; Scagliotti GV; Shimizu K; Stopeck A
    J Bone Oncol; 2022 Apr; 33():100416. PubMed ID: 35242510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
    Kohno N
    Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
    Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
    J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of bone metastases in refractory prostate cancer--role of denosumab.
    Paller CJ; Carducci MA; Philips GK
    Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours.
    Scott LJ; Muir VJ
    Drugs; 2011 May; 71(8):1059-69. PubMed ID: 21668042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab for the treatment of bone metastases in advanced breast cancer.
    Casas A; Llombart A; Martín M
    Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palliative Oncology: Denosumab.
    Prommer E
    Am J Hosp Palliat Care; 2015 Aug; 32(5):568-72. PubMed ID: 24928835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
    Smith MR
    Urol Oncol; 2008; 26(4):420-5. PubMed ID: 18593621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.
    Clemons M; Gelmon KA; Pritchard KI; Paterson AH
    Curr Oncol; 2012 Oct; 19(5):259-68. PubMed ID: 23144574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
    J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab: A comprehensive review.
    Narayanan P
    South Asian J Cancer; 2013 Oct; 2(4):272-7. PubMed ID: 24455656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
    Lipton A; Balakumaran A
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2009 Aug; 182(2):509-15; discussion 515-6. PubMed ID: 19524963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.
    Campbell-Baird C; Harrelson S; Frey G; Balakumaran A
    Support Care Cancer; 2015 Dec; 23(12):3625-32. PubMed ID: 26298333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.